tbuckley/cabot-search huggingface dataset:
TMOD-30. CHARACTERIZATION OF AN ALTERNATIVELY SPLICED NTRK2 VARIANT IN GLIOMAS
Authors: Siobhan Pattwell, Sonali Arora, P J Cimino, Frank Szulzewsky, Pia Hoellerbauer, Benjamin Hoffstrom, Norman Boiani, Tatsuya Ozawa, Hamid Bolouri, Colin Correnti, John Silber, Patrick Paddison, Eric Holland
Journal: Neuro-Oncology (2019)

Abstract Recent work has uncovered oncogenic TRK fusions in a wide range of cancer types, including adult and pediatric gliomas. With some exceptions, many of these fusions tend to occur at very low frequencies below 1–2%, with unclear clinical significance, yet they highlight a potentially important and rapidly evolving role for NTRK1, NTRK2, NTRK3 in glioma biology. Basic scientific and clinical investigation surrounding TRKs’ role in cancer has often been hindered due to the nonspecific nature of antibodies and kinase inhibitors, combined with a lack of precise exon-specific expression data from patient populations. Tropomyosin receptor B (TrkB), encoded by the NTRK2 gene, is most known for its established roles in neuronal survival, proliferation, differentiation, apoptosis, learning, and memory. TrkB exerts diverse effects on cellular outcomes through interactions with downstream signaling cascades and has been shown to exhibit complex alternative splicing patterns. Here we show a novel role for a TrkB splice variant in human gliomas via NTRK2 transcript analyses in normal human brain and gliomas using The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression Project (GTEx). Using a novel antibody designed against this splice variant, immunostaining shows altered receptor localization within human gliomas compared to normal human brain. This NTRK2 splice variant enhances PDGF-driven gliomas in vivo in an RCAS-TVA mouse model and augments PDGF-induced signaling in vitro. Through the lens of NTRK2, these results highlight the importance of expanding upon whole gene-level and kinase-fusion analyses to explore TRK splicing in basic and translational research.
Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: Systematic review and Bayesian network meta-analysis
Authors: Hyun Woo Lee, Jimyung Park, Junwoo Jo, Eun Jin Jang, Chang-Hoon Lee
Journal: PLoS Medicine (2019)

Background Although exacerbation and mortality are the most important clinical outcomes of stable chronic obstructive pulmonary disease (COPD), the drug classes that are the most efficacious in reducing exacerbation and mortality among all possible inhaled drugs have not been determined. Methods and findings We performed a systematic review (SR) and Bayesian network meta-analysis (NMA). We searched Medline, EMBASE, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, the European Union Clinical Trials Register, and the official websites of pharmaceutical companies (from inception to July 9, 2019). The eligibility criteria were as follows: (1) parallel-design randomized controlled trials (RCTs); (2) adults with stable COPD; (3) comparisons among long-acting muscarinic antagonists (LAMAs), long-acting beta-agonists (LABAs), inhaled corticosteroids (ICSs), combined treatment (ICS/LAMA/LABA, LAMA/LABA, or ICS/LABA), or a placebo; and (4) study duration ≥ 12 weeks. This study was prospectively registered in International Prospective Register of Systematic Reviews (PROSPERO; CRD42017069087). In total, 219 trials involving 228,710 patients were included. Compared with placebo, all drug classes significantly reduced the total exacerbations and moderate to severe exacerbations. ICS/LAMA/LABA was the most efficacious treatment for reducing the exacerbation risk (odds ratio [OR] = 0.57; 95% credible interval [CrI] 0.50–0.64; posterior probability of OR > 1 [P(OR > 1)] < 0.001). In addition, in contrast to the other drug classes, ICS/LAMA/LABA and ICS/LABA were associated with a significantly higher probability of reducing mortality than placebo (OR = 0.74, 95% CrI 0.59–0.93, P[OR > 1] = 0.004; and OR = 0.86, 95% CrI 0.76–0.98, P[OR > 1] = 0.015, respectively). The results minimally changed, even in various sensitivity and covariate-adjusted meta-regression analyses. ICS/LAMA/LABA tended to lower the risk of cardiovascular mortality but did not show significant results. ICS/LAMA/LABA increased the probability of pneumonia (OR for triple therapy = 1.56; 95% CrI 1.19–2.03; P[OR > 1] = 1.000). The main limitation is that there were few RCTs including only less symptomatic patients or patients at a low risk. Conclusions These findings suggest that triple therapy can potentially be the best option for stable COPD patients in terms of reducing exacerbation and all-cause mortality.
Maintenance Therapy with Decitabine after Allogeneic Hematopoietic Stem Cell Transplantation to Prevent Relapse of High Risk Acute Myeloid Leukemia
Authors: Yunju Ma, Changju Qu, Haiping Dai, Jia Yin, Zheng Li, Jia Chen, Huiying Qiu, Aining Sun, Miao Miao, Chengcheng Fu, Zhengming Jin, Xiaming Zhu, Depei Wu, Xiaowen Tang
Journal: Blood (2019)
RTHP-32. FIRST EXPERIENCE WITH GAMMATILE PERMANENT IMPLANTS FOR RECURRENT BRAIN TUMORS
Authors: Clara Ferreira, Parham Alaei, Clark Chen, Margaret Reynolds, David Sterling, Kathryn Dusenbery
Journal: Neuro-Oncology (2019)

Abstract GammatileTM permanent brachytherapy implants have been FDA cleared for patients with recurrent brain tumors. We report our experience with the first 6 patients with recurrent high grade primary brain tumors treated with re-resection and implantation. Each tile contains 4 encapsulated radioactive Cs-131 seeds embedded in collagen. To determine the number of tiles needed, the potential tumor cavity surface area was estimated using the preoperative MRI images. The anticipated cavity surface area was calculated, the surface area of anticipated surgical approach was subtracted. This area was divided by 40mm2 (tile area) and this number of tiles were ordered. At the time of surgery, after maximal safe tumor resection, tiles were placed into the resection cavity and the surgical cavity closed as usual. On post-implant day 1, CT and MRI scans were performed. The cavity was contoured, then expanded by 5mm to create HRCTV. T1 MRI enhanced lesions were contoured as residual GTV (GTVr). A dose of 60Gy over the course of treatment was prescribed to HRCTV. In each of these 6 cases, over 95% of the HRCTV was covered by the 60Gy isodose surface, and GTVr D90 ranged from 22.9Gy to 113.8Gy. The additional time required for the tile placement in all cases was less than 10 minutes. Post-operatively exposure rates at 1m were less than 6 mR/hr (ranging from 1.3 to 3.2mR/h). Permanent GammaTile for recurrent brain tumors is a viable option for selected previously irradiated patients who are operative candidates. Benefits include irradiation of the tumor bed starting immediately after resection with no need to wait for wound healing, and no need to subsequently surgically remove the tile. We were able to accurately predict the number of tiles needed, although in one case collagen spacers were utilized. Due to low exposure rates, radiation protection issues are very manageable.
Diagnostic Delay and Characterization of the Clinical Prodrome in AL Amyloidosis: Data from 1,313 US Commercially Insured Patients between 2006-2018
Authors: Laura L Hester, Dina M Gifkins, Kevin M Bellew, Jessica Vermeulen, Jordan M Schecter, Frank J DeFalco, Brendan M Weiss
Journal: Blood (2019)
CSIG-20. EFFECT OF TUMOR-TREATING FIELDS (TTFIELDS) ON EGFR PHOSPHORYLATION IN GBM CELL LINES
Authors: Maria Luisa D’Angelo, Deborah Piffaretti, Floriana Burgio, Alessio Chiappini, Francesco Marchi, Michael Reinert
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) is the most common high grade and most devastating brain tumor among adults. About 50% of GBM express EGFR (epidermal growth factor receptor) and from these another 50% the mutated form EGFRvIII which is associated with a more aggressive disease and poorer prognosis. We have previously shown that expression of different status of EGFR in GBM cell lines drives the 5-ALA induced fluorescence downstream by influencing the rate-limiting enzyme heme oxygenase-1 (HO-1) probably via PI3K/Akt signalling. We demonstrated that 5-ALA-induced protoporphyrin IX (PpIX) fluorescence is pharmacologically influenced by adding different drugs such as deferoxamine (DFO) and tin-protoporphyrin (SnPP), which are an iron chelator of Fe2+ and an inhibitor of HO-1 respectively, or genistein that promotes PpIX accumulation via functional repression of ABCG2 (ABC transporter G2). Our aim is to increase these pharmacological effects on PpIX fluorescence using tumor-treating fields (TTFields). TTFields, a new therapeutic technology for treating newly diagnosed or recurrent GBM, is able to suppress the growth of cancer cells destabilising microtubule elongation and increasing membrane permeability. Interestingly, TTFields, like as other destabilising drugs and compounds, is able to inhibit the phosphorylation of EGFR and subsequent downregulation of EGFR-induced signalling acting for example on the mechanism that regulate the HO-1 activity. Here, we investigate the effects of TTFields on glioma cells, with different EGFR status and consequently different PpIX fluorescence. Exposure to TTFields during or after pharmacological treatments may represent a novel strategy to block or diminish the phosphorylation of EGFR to ameliorate the visualization of PpIX fluorescence in patients where it is not enough to ensure a safe and precise removal of the tumor bulk. In fact, if a combination of TTFields and drug treatment should give the desired results, this strategy could be applied on patients before being subjected to surgical resection.
A CXCL10/CXCR3 Driven Thymic Epithelium-Leukemia Cell Crosstalk Augments T Cell Acute Lymphoblastic Leukemia Notch1 Signalling
Authors: Ashwini M Patil, Stefanie Kesper, Vishal Khairnar, Marco Luciani, Michael Möllmann, Ulrich Dührsen, Joachim R Göthert
Journal: Blood (2019)
Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance
Authors: Jonas Paludo, Surendra Dasari, Kerstin Wenzl, Shahrzad Jalali, Jordan Krull, Michelle Manske, Esteban Braggio, Prashant Kapoor, Aneel Paulus, Sikander Ailawadhi, Craig B. Reeder, Allison C. Rosenthal, Robert A. Kyle, Morie A Gertz, Anne J Novak, Stephen M Ansell
Journal: Blood (2019)
Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
Authors: Jesus G. Berdeja, Melissa Alsina, Nina D. Shah, David S. Siegel, Sundar Jagannath, Deepu Madduri, Jonathan L. Kaufman, Nikhil C. Munshi, Jacalyn Rosenblatt, Jagoda K. Jasielec, Yi Lin, Ashley Turka, Lyh Ping Lam, Monica Massaro, Timothy B. Campbell, Kristen Hege, Fabio Petrocca, Noopur S. Raje
Journal: Blood (2019)
Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): Analysis of African American patients.
Authors: David N. Hayes, Guangbin Peng, Eduardo Pennella, Gebra Cuyun Carter, Catherine E. Muehlenbein, Kelly L. Covello, Mitra Corral, Coleman Obasaju
Journal: Journal of Clinical Oncology (2012)

5533 Background: Previous retrospective analyses show poor outcomes for African American (AA) patients with head and neck carcinoma (HNC). Such racial disparities are not well understood, but patient (pt) demographics, comorbidities, tumor site, and human papillomavirus (HPV) status are suggested to play a role. Methods: The LORHAN registry was used to identify pts ≥18 yrs of age with de novo, non-metastatic HNC, and a record of survival time. This study evaluated pt and treatment characteristics by race, and conducted adjusted Cox regression analyses of overall survival (OS) and progression-free survival (PFS) to identify prognostic factors and interactions, and estimate hazard ratios (HRs) of AA vs. non-Hispanic white (NHW). Results: Baseline pt characteristics (see table below). The median OS/3-yr rate was 41.7 mo/51% in AA vs. 52.9 mo/70% in NHW, (age-adjusted HR: 1.73 [95% CI: 1.45, 2.08]). The median PFS/3-yr rate was 29.6 mo/43% in AA and 49.9 mo/62% in NHW, (age-adjusted HR: 1.64 [95%CI: 1.40, 1.93]). Multivariate analysis of OS and PFS showed that AA race, stage III and IV, PS 2, and smoking were significantly associated with a worse HR, while OP demonstrated a favorable HR over other sites. Significant interaction tests led to subgroup analyses for OS showing an elevated risk in AA with OP (HR: 2.62 [95%CI: 1.95, 3.52]) and similar risk elevations in male AA as well as in AA with PS 0-1 when compared to NHW in the corresponding subgroups. Conclusions: Controlling for other factors like PS and smoking, a worse prognosis was seen in AA males with OP localized SCCHN. Further investigation to improve the outcomes in this population is warranted. [Table: see text]
Preemptive Therapy Based on the Load and Time of EBV-Emia for Preventing EBV Related PTLD after Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective Multicenter Study
Authors: Can Liu, Ren Lin, Yu Wang, Fen Huang, Zhiping Fan, Shen Zhang, Yajing Xu, Ting Yang, Li Xuan, Na Xu, Jieyu Ye, Jing Sun, Xiaojun Huang, Qifa Liu
Journal: Blood (2019)
IMMU-04. TEMPORAL AND SPATIAL MODULATION OF THE IMMUNE RESPONSE OF THE MURINE GL261 GLIOMA TUMOUR MICROENVIRONMENT
Authors: Kelly McKelvey, Amanda Hudson, Ramyashree Kumar, Georgina Long, Richard Scolyer, James Wilmott, Grace Attrill, Stephen Clarke, Helen Wheeler, Connie Diakos, Viive Howell
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Glioma is a debilitating and early fatal cancer arising in the glial cells of brain. Glioblastoma, the most aggressive form of gliomas, has a 5-year survival rate of 5% with treatment options limited to surgery, radiotherapy or chemotherapy with temozolomide. OBJECTIVE While radiation and immunotherapies are routinely studied in the murine Gl261 glioma model, little is known about its inherent immune response. In this study we quantified the temporal and spatial localisation of immune cell populations and mediators during glioma development. METHODS Mice were inoculated with 1x106 Gl261 cells at AP0.1mm, ML1.0mm, DV2.6mm Bregma. Tumour morphology, local and systemic immune cell populations were assessed at Day-0, 1, 3, 7, 14, and 21 post-inoculation by MRI, immunohistochemistry for Ki67+ proliferation and CD31+ vessel density; local immune infiltrate by multiplex immunofluorescence (VECTRA®;PerkinElmer); systemic immunity in spleen, bone marrow and peripheral blood by 16-parameter flow cytometry (LSRFortessa™;BD Biosciences); and multiplex immunoassay (Bio-Plex®;Bio-Rad) for plasma cytokines/chemokines. RESULTS From Day-3 tumours were distinguishable with high Ki67+ (&gt; 30%) and increased tissue vascularisation (26.38±1.45 vessels/field; p&lt; 0.05). Ki67 remained high until Day-21 with visible necrotic regions, increased vessel density and lumen area within tumour region. Increasing tumour proliferation/malignancy and vascularisation were associated with significant temporal changes in immune cell populations within the tumour (p&lt; 0.05) and systemic compartments (p=0.02- p&lt; 0.0001). Of note, at Day-14 NK, M1, PMN-MDSCs and M-MDSCs in the tumour infiltrate declined, coinciding with a decrease in 16/24 plasma cytokine/chemokines levels. Tumour infiltrating immune cell populations did not correlate with peripheral blood populations. However, a decrease in plasma cytokine/chemokine levels may indicate ‘immune exhaustion’. CONCLUSIONS The data derived provide baseline characteristics to study changes associated with multi-modal treatment strategies and to sequence therapies to maintain immune modulation. This information will contribute to the identification of novel combination therapies.
Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia
Authors: Mrinal M Patnaik, Daniela Barraco, Terra L. Lasho, Ezequiel Tolosa, Luciana L. Almada, Jaime I Davila, Christy Finke, Curtis A. Hanson, Rhett P. Ketterling, Éric Solary, Nathalie M. Droin, Naseema Gangat, Aref Al-Kali, Martin E. Fernandez-Zapico, Ayalew Tefferi
Journal: Blood (2016)
Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial
Authors: David Chiron, Celine Bellanger, Antonin Papin, Benoit Tessoulin, Christelle Dousset, Sophie Maiga, Anne Moreau, Julie Esbelin, Valerie Trichet, Selina Chen-Kiang, Philippe Moreau, Cyrille Touzeau, Steven Le Gouill, Martine Amiot, Catherine Pellat-Deceunynck
Journal: Blood (2016)
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
Authors: Jeff P. Sharman, Versha Banerji, Laura Maria Fogliatto, Yair Herishanu, Talha Munir, Renata Walewska, George Follows, Karin Karlsson, Paolo Ghia, Gillian Corbett, Patricia Walker, Miklos Egyed, Wojciech Jurczak, Gilles Salles, Ann Janssens, Florence Cymbalista, William G. Wierda, Steven Coutre, John M. Pagel, Alan Skarbnik, Manali Kamdar, Jennifer Woyach, Raquel Izumi, Veerendra Munugalavadla, Priti Patel, Min Hui Wang, Sofia Wong, John C. Byrd
Journal: Blood (2019)
Leprosy and its Problems
Authors: N. Dungal
Journal: BMJ (1947)

divisions-extractions, by which the whole varicose vein could be extirpated through incisions-rarely more than 1/4 to 1/3 in. (0.63-0.85 cm.) in length-at intervals along the vein, the sites for incision carefully selected in the standing patient and indelibly marked before operation.The incisions, Wiade parallel to the lines of tension of the skin, gape but little and do not require suLturing.Only very few ligations of severed veins are ever necessary, and perforating veins and tributaries can be divided and ligated or, if small, torn off flush with the deep fascia with- out the use of a vein enucleator.In some cases new varicose veins have appeared so soon after extirpation of the old as to raise inescapably the question of overloading in the deep veins and a new compensatory reflux through deep communicating veins, and the wisdom of severing all deep communications, if that were feasible.Here I take opportunity to record my indebtedness to Mr.
Prosthetic Valve Endocarditis After TAVR and SAVR
Authors: Matthew R. Summers, Martin B. Leon, Craig R. Smith, Susheel K. Kodali, Vinod H. Thourani, Howard C. Herrmann, Raj R. Makkar, Philippe Pibarot, John G. Webb, Jonathon Leipsic, Maria C. Alu, Aaron Crowley, Rebecca T. Hahn, Samir R. Kapadia, E. Murat Tuzcu, Lars Svensson, Paul C. Cremer, Wael A. Jaber
Journal: Circulation (2019)

Background: Prosthetic valve endocarditis (PVE) is a rare but critical mechanism of valve failure and death after transcatheter and surgical aortic valve replacement (TAVR, SAVR) warranting further analysis in modern aortic valve replacement experience. We characterize the incidence, risk factors, microbiological profile and outcomes of PVE from the PARTNER trials and registries (Placement of Aortic Transcatheter Valve). Methods: We analyzed a pooled cohort of all patients in PARTNER 1 and PARTNER 2 trials and registries. Patients had severe aortic stenosis, were treated with TAVR or SAVR, and were analyzed with respect to development of PVE. PVE adjudication by a clinical events committee was based on modified Duke Criteria. The incidence, infection timing, organism, and association between PVE and all-cause mortality were analyzed. Results: 8530 patients were included. PVE occurred in 107 cases (5.06 PVE events per 1000 person-years over a mean follow-up of 2.69±1.55 years [95% CI, 4.19–6.12]). The incidence of TAVR-PVE (5.21 PVE per 1000 person-years [95% CI, 4.26–6.38]) was not significantly different from SAVR-PVE (4.10 per 1000 person-years [95% CI, 2.33–7.22]; incident rate ratio, 1.27 [95% CI, 0.70–2.32]; P =0.44). Temporal risk of PVE was similar for TAVR and SAVR, even after adjusting for competing risk of death (hazard ratio, 1.15 [95% CI, 0.58–2.28]; P =0.69). Through multivariable analysis, PVE was associated with baseline cirrhosis (incident rate ratio, 2.86 [95% CI, 1.33–6.16]; P =0.007), pulmonary disease (incident rate ratio, 1.70 [95% CI, 1.16–2.48]; P =0.006), and renal insufficiency (incident rate ratio, 1.71 [95% CI, 1.03–2.83]; P =0.04). Timing of PVE was similar between TAVR and SAVR (&lt;30 days: 4.2% vs 8.3%; 31 days to 1 year: 52.6% vs 66.7%; &gt;1 year: 43.2% vs 25.0%; P =0.28). Staphylococcus occurred more commonly after SAVR (58.3% vs 28.4% in TAVR; P =0.04). PVE was strongly associated with all-cause mortality after endocarditis diagnosis (hazard ratio, 4.4 [95% CI, 3.42–5.72]; P &lt;0.0001). Conclusions: The widespread adoption of TAVR and application to lower-risk patients makes understanding mechanisms of valve failure increasingly important. PVE is an established mechanism of prosthetic valve failure post-SAVR and TAVR with unclear differences between approaches. We herein demonstrate in the largest trials and registries of TAVR that PVE remains rare, but often fatal, in modern AVR experience and that there is no difference in incidence, predictors, or risk of PVE between TAVR and SAVR. Clinical Trial Registration: https://www.clinicaltrials.gov . Unique identifiers: NCT00530894 (PARTNER 1), NCT01314313 (PARTNER 1IA), NCT02184442 (PARTNER 1IB), NCT03222141 (PII S3HR), NCT03222128 (PII S3i).
Myopathy in Metabolic Bone Disease
Authors: J. W. Prineas, A. S. Mason, R. A. Henson
Journal: BMJ (1965)

Intestinal Malabsorption-Rose BRIui not determined, but there was no haematological evidence of folic-acid deficiency.Kershaw and Girdwood (1964) found two out of six patients with disseminated carcinoma to have low serum folic-acid levels and increased Figlu excretions, and Girdwood (1953b) has reported evidence of folic-acid deficiency in this condition.The most likely explanation for such cases is that there is an increased demand for folic acid due to the proliferation of malignant cells.Dymock (1964a) has estimated the urinary excretion of urocanic acid and Figlu in 28 patients with malignant disease, and in 24 the outputs were abnormal.He did not measure the serum folic-acid levels, and in 10 cases there was some evidence of liver dysfunction (Dymock, 1964b).It is possible, therefore, that in some cases of disseminated malignancy the abnormal Figlu excretion results from an impairment of hepatic Figlu transferase activity.A rapid turnover of folic acid may have contributed to the folic-acid deficiency observed in the three patients with lymphosarcoma and the patient with chronic lymphocytic leukaemia.Abnormal Figlu excretions occur frequently in both acute and chronic leukaemias and reticuloses, and in such cases the serum folic-acid levels are often low (Rose, 1964). SummaryThe excretion of Figlu in the urine has been estimated in 35 patients with a variety of diseases accompanied by intestinal malabsorption.It is concluded that although the Figlu excre- tion test is of limited value for screening patients with suspected idiopathic steatorrhoea, such a diagnosis is unlikely if the Figlu excretion is normal.It is suggested that the urinary Figlu excretion and the urinary xylose-excretion test used in combination provide a simple means of assessing jejunal function in patients with small-bowel disease.
Erratum: Themis, a T cell–specific protein important for late thymocyte development
Authors: Renaud Lesourne, Shoji Uehara, Jan Lee, Ki-Duk Song, LiQi Li, Julia Pinkhasov, Yongqing Zhang, Nan-Ping Weng, Kathryn F Wildt, Lie Wang, Remy Bosselut, Paul E Love
Journal: Nature Immunology (2009)
The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma
Authors: Ning Xu, Nicole Ng, Mingjie Li, Erin Yu, Eric Sanchez, Sean Bujarski, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Janna Yu, Justin Huang, David Daniely, Cathy S. Wang, Haiming Chen, James R. Berenson
Journal: Blood (2019)